

CancerPACT™



Cancer Patients' Alliance for Clinical Trials

Denver area adult cancer clinical trials

Fall 2008

I. Solid Tumors

1.	Breast	p.1
2.	Central Nervous System	p.4
3.	Gastrointestinal	p.5
4.	Gynecologic	p.7
5.	Head & Neck	p.8
6.	Lung	p.8
7.	Melanoma	p.10
8.	Prostate	p.10
9.	Sarcoma	p.11
10.	Urologic (other)	p.11

II. Hematologic Cancers

1.	Leukemia	p.12
2.	Lymphoma	p.13
3.	Myeloma	p.14

III.	Other	p.14
------	-------	------

I. Solid Tumors

1. Breast Cancer

1. Phase III Trial of Continuous Shedule AC + G vs q2wk Schedule AC, Followed by Paclitaxel Given Either Every 2 weeks or Weekly for 12 weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node Negative Breast Cancer (DH, UCCC)
2. Phase III Trial Evaluating the Role of Exemestane Plus GnRH Analogue as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast Cancer (UCCC, RMCC)

HOTLINE: 1-888-729-0244

Colorado Cancer Research Program (CCRP) 303-777-2663; Denver Health (DH) 303-436-5774; Rocky Mountain Cancer Centers (RMCC) 1-888-259-7622; University of Colorado Cancer Center (UCCC) 720-848-0018

CancerPACT is a program presented by the Colorado Cancer Research Program, Colorado Cancer Coalition, Colorado Department of Public Health and Environment, Denver Health, Lorenzen Cancer Foundation, and University of Colorado Cancer Center

www.CancerPACT.org

3. Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation for Women With Stage 0, I, or II Breast Cancer (RMCC, CCRP, UCCC)
4. **Phase III Randomized Study Cyclophosphamide and Doxorubicin (CA) (4 VS 6 Cycles) Versus Paclitaxel (4 VS 6 Cycles) As Adjuvant Therapy For Breast Cancer in Women with 0-3 Positive Axillary Lymph Nodes: A 2X2 Factorial (RMCC, CCRP)**
5. Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer (DH, UCCC)
6. **Phase III Study Of SU011248 In Combination With Paclitaxel Versus Bevacizumab With Paclitaxel In The First-Line Advanced Disease Setting In Patients Having Breast Cancer (RMCC)**
7. Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women with Endocrine Responsive Breast Cancer (RMCC, CCRP)
8. **Randomized, Double-blind, Placebo Controlled Study to Evaluate AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy For Non-Metastatic Breast Cancer (RMCC)**
9. Open Label, Randomized Parallel Two-Arm Multi Center Study of E7389 versus 'Treatment of Physician's Choice' in Patients with Locally Recurrent or Metastatic Breast Cancer, Previously Treated with At Least Two and a Maximum of Five Prior Chemotherapy Regimens, Including an Anthracycline and a Taxane (RMCC)
10. **Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer (RMCC)**
11. Phase III Trial of Neoadjuvant Therapy for Patients with Palpable and Operable HER2-Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab and to Lapatinib Administered with Weekly Paclitaxel Following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response (RMCC, CCRP, RMCC)
12. **Phase III trial of adjuvant TC vs TAC in HER-2 negative early stage breast cancer patients (RMCC)**
13. Phase II Randomized Trial of Anastrozole Versus Anastrozole and Fulvestrant as First Line Therapy for Post Menopausal Women with Metastatic Breast cancer (DH)
14. **A Prospective, Randomized, Double-Blind, Stratified, Multi-Center Two-arm Trial of the Continued Efficacy and Safety of Zometa (every 4 weeks vs. every 12 weeks) in Patients With Documented Bone Metastases from Breast Cancer (DH)**
15. Phase II Trial of Combination Therapy with Xeloda and Weekly Paclitaxel for Metastatic Breast Cancer (RMCC)
16. **Phase II Randomized Trial of Gemcitabine/Carboplatin, with or without BSI-201, in patients with ER, PR, and HER2-negative metastatic breast cancer (RMCC)**
17. Phase II Clinical Trial of Epirubicin Plus Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and Bevacizumab Given as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or Given as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer (CCRP; UCCC)
18. **Phase II, Single-Arm, Open-Label Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients with HER2-Positive Metastatic Breast Cancer Who Have Progressed while Receiving HER2-Directed Therapy (RMCC)**
19. Phase II Study of Sorafenib Compared to Placebo When Administered in Combination with Aromatase Inhibitors for Patients with Metastatic Breast Cancer (CCRP, RMCC)
20. **Phase II, multicenter, open-label, clinical trial of Trabectedin (Yondelis®) in Metastatic Breast Cancer Patients with triple negative profile (ER-, PR-, HER2-), HER2 overexpressing tumors and BRCA1 or BRCA2 mutation carriers (RMCC)**
21. Phase II Study of Neoadjuvant Chemotherapy with Sequential Weekly Nanoparticle Albumin Bound Paclitaxel (Abraxane) Followed by 5-FU, Epirubicin, Cyclophosphamide (FEC) in Locally Advanced Breast Cancer (RMCC)

HOTLINE: 1-888-729-0244

Colorado Cancer Research Program (CCRP) 303-777-2663; Denver Health (DH) 303-436-5774;
Rocky Mountain Cancer Centers (RMCC) 1-888-259-7622; University of Colorado Cancer
Center (UCCC) 720-848-0018

CancerPACT is a program presented by the Colorado Cancer Research Program, Colorado Cancer Coalition,
Colorado Department of Public Health and Environment, Denver Health, Lorenzen Cancer Foundation, and
University of Colorado Cancer Center

www.CancerPACT.org

22. **Phase IIB Double-Blind, Randomized Study of Sorafenib Compared to Placebo when Administered in Combination with Chemotherapy for Patients with Locally Advanced or Metastatic Breast Cancer that has Progressed During or Following Bevacizumab Therapy (RMCC)**
23. Phase II Treatment protocol for patients continuing from a prior SU011248 protocol (UCCC)
24. **Randomized Clinical Trial of Adjuvant Chemotherapy for Radically Resected Loco-Regional Relapse of Breast Cancer (CCRP, RMCC)**
25. Adjuvant Therapy Comparing Six Cycles of 5-FU, Epirubicin and Cyclophosphamide (FEC) to Four Cycles of Adriamycin and Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer (CCRP; UCCC)
26. **Phase II Differential Gene Regulation During Neoadjuvant Therapy Trial of Epirubicin/ (EC) vs Docetaxel/Capecitabine (DX) Regimens in Patients with Large ER-positive and ER-negative Breast Cancers (UCCC)**
27. Double-Blind Re-Randomization to Letrozole or Placebo for Women Completing 5 Years of Adjuvant Letrozole in the MA.17 Study (RMCC, CCRP)
28. **Clinical Trial to Determine the Efficacy of 5 Years of Letrozole Compared to Placebo in Patients Completing 5 Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease Free Survival in Post Menopausal Women with Hormone Receptor Positive Breast Cancer (CCRP, RMCC, UCCC)**
29. Program for the Assessment of Clinical Cancer Tests - Trial Assigning Individualized Options for Treatment: The TAILORx Trial (CCRP, RMCC, UCCC)
30. **Phase II Multi-center Study to Evaluate the Efficacy and Safety of 500mg of Fulvestrant (Faslodex) as a First Line Hormonal Treatment in Postmenopausal Women with Hormone Receptor Positive Metastatic Breast Cancer (UCCC)**
31. Phase II Study of Fulvestrant in Premenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer (UCCC)
32. **Phase II Study of Accelerated Partial Breast Radiotherapy With Either a Novel Breast Brachytherapy Technique - Mammosite or Intensity Modulated Radiotherapy (RMCC)**
33. PK, PD and Safety Study of Zometa q1 vs.q3 month, in Multiple Myeloma patients with malignant bone lesions, and breast cancer patients with bone metastasis, post 9 to 12 doses of Zometa over the prior year (RMCC)
34. **Phase 1-2, Multicenter, Open-Label Study of the X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 Given in Combination with Weekly Paclitaxel in Patients with Advanced Breast Cancer (RMCC)**
35. Phase I Study of MK-0752, a Notch Inhibitor, in Patients With Metastatic or Locally Advanced Breast Cancer (RMCC)
36. **Lapatinib in Endocrine-Resistant Metastatic Breast Cancer (UCCC)**
37. Phase III Trial to Test the Strategy of Changing Therapy vs Maintaining Therapy for Metastatic Breast Cancer Patients Who Have Elevated Circulating Tumor Cell Levels at First Follow Up Assessment. (UCCC)
38. **Pilot Study of Stimulation of Immune Responses in Human Breast Cancer By a Novel Vaccine (UCCC)**
39. Protein Profiles of Invasive Breast Cancer in Tissue and Blood (UCCC)
40. **Breast Cancer Tissue Bank (UCCC)**
41. Exempt Trial - Lobular Carcinoma of the Breast: Clinical Database and Tissue Microarray Study (UCCC)
42. **Proteomic Profiles of Plasma in Healthy Women Getting Mammographic Screening (UCCC)**
43. Chemotherapy and Cognition in Older Breast Cancer Patients (RMCC)
44. ALTTO: Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation Study: A Randomised, Multi-centre, Open-label, Phase III Study of Adjuvant Lapatinib, Trastuzumab, Their Sequence and Their Combination in Patients with HER2/ErbB2 Positive Primary Breast Cancer (CCRP)

HOTLINE: 1-888-729-0244

Colorado Cancer Research Program (CCRP) 303-777-2663; Denver Health (DH) 303-436-5774;
Rocky Mountain Cancer Centers (RMCC) 1-888-259-7622; University of Colorado Cancer
Center (UCCC) 720-848-0018

CancerPACT is a program presented by the Colorado Cancer Research Program, Colorado Cancer Coalition,
Colorado Department of Public Health and Environment, Denver Health, Lorenzen Cancer Foundation, and
University of Colorado Cancer Center

www.CancerPACT.org

45. **A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer (CCRP)**
46. BETH: Bevacizumab with Trastuzumab Adjuvant Therapy in HER2+ Breast Cancer -- A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemotherapy Plus Trastuzumab Plus Bevacizumab (CCRP)

2. Central Nervous System Tumors

1. **Phase III Randomized Trial of the Role of Whole Brain Radiation Therapy in Addition to Radiosurgery in the of Patients with One to Three Cerebral Metastases NCCTG N0547 (UCCC)**
2. Phase III Open-Label, Extended-Use Study of Human Corticotropin Releasing Factor (hCRF) Intended for Patients Who Participate in the Dexamethasone-Sparing Studies NTI 0302 or NTI 0303 (UCCC)
3. **Phase III Randomized, Double-Blind, Dexamethasone-Sparing Study Comparing Human Corticotropin-Releasing Factor (hCRF) to Placebo for Control of Symptoms Associated with Peritumoral Brain Edema in Patients with Malignant Brain Tumor (UCCC)**
4. Extended-Use Study of Human Corticotropin Releasing Factor (hCRF) Intended for Patients Who Participate in the Dexamethasone-Sparing Studies NTI 0302 or NTI 0303 (UCCC)
5. **Studies to determine the presence of SV40 virus-like sequences and anti-SV40 antibodies in patients with neuroblastoma and central nervous system brain tumors (UCCC)**
6. Phase III Trial Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy (1800 Gy) and Chemotherapy in Children with Newly Diagnosed Standard Risk Medulloblastoma (UCCC)
7. **Phase III Randomized Study of Chimeric Anti-GD2 in High risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue (UCCC)**
8. **Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients with Newly Diagnosed Low-Risk Embryonal/Botryoid Rhabdomyosarcoma (UCCC)**
9. Phase I/II study of Hypofractionated Stereotactic Radiotherapy in Combination with ZD1839 (IRESSA) in Patients with Recurrent Malignant Gliomas. (UCCC)
10. **Phase I Dose Per Fraction Escalation Study of Hypofractionated Intensity-Modulated Radiation Therapy (Hypo-IMRT) Combining with Temozolomide (TMZ) Chemotherapy for Patients with newly diagnosed Glioblastoma Multiforme (GBM) (DH, UCCC)**
11. Phase I/II trial of Temozolomide, Motexafin Gadolinium, and 60 GY Fractionated Radiation for Newly Diagnosed Supratentorial Glioblastoma Multiforme (UCCC)
12. Neuroblastoma Biology Studies (UCCC)

HOTLINE: 1-888-729-0244

Colorado Cancer Research Program (CCRP) 303-777-2663; Denver Health (DH) 303-436-5774; Rocky Mountain Cancer Centers (RMCC) 1-888-259-7622; University of Colorado Cancer Center (UCCC) 720-848-0018

CancerPACT is a program presented by the Colorado Cancer Research Program, Colorado Cancer Coalition, Colorado Department of Public Health and Environment, Denver Health, Lorenzen Cancer Foundation, and University of Colorado Cancer Center

www.CancerPACT.org

3. Gastrointestinal Cancers

A. Colorectal Cancer

1. Clinical Trial Comparing Preoperative Radiation Therapy and Capecitabine with Preoperative Radiation Therapy and Continuous Intravenous Infusion (CVI) of 5-Fluorouracil (5-FU) in the Treatment of Patients with Operable Carcinoma of the Rectum (CCRP, RMCC, UCCC)
2. **Phase III Intergroup Trial of Adjuvant Chemoradiation After Resection of Gastric or Gastroesophageal Adenocarcinoma (CCRP RMCC,)**
3. Phase III Trial of Irinotecan, 5-FU, Leucovorin or OXaliplatin, 5-FU, Leucovorin with Bevacizumab or Cetuximab or With the Combination of Bevacizumab and Cetuximab For Patients With Untreated Metastatic Adenocarcinoma of the Colon or Rectum (CCRP, DH, RMCC, UCCC)
4. **Phase III Randomized Study of Postoperative Oxaliplatin, 5-Fluorouracil and Leucovorin vs Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Pre-operative Chemoradiation (CCRP, RMCC)**
5. Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin vs. 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers (DH, CCRP; UCCC)
6. **Phase III Study of Xaliproden as a Neuro-protective Agent in Patients Receiveing Oxaliplatin/5-FU/LV (UCCC)**
7. Phase III Trial of Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU) / Leucovorin (LV) With or Without Cetuximab (C225) After Curative Resection for Patients With Stage III Colon Cancer (CCRP, RMCC)
8. **Phase II Trial of Taxotere + Eloxatin in Patients with Metastatic Gastric and/or Gastroesophageal Junction Adenocarcinoma (RMCC)**
9. Phase II Clinical Trial Evaluating Safety and Efficacy of FOLFIRI with Either Panitumumab or Bevacizumab as Second-line Treatment in Subjects with Metastatic Colorectal Cancer (RMCC)
10. **Phase II Study of Docetaxel in Combination with Oxaliplatin with or without 5-FU or Capecitabine in Metastatic or Locally Recurrent Gastric Cancer previously untreated with Chemotherapy for Advanced Disease (RMCC)**
11. Phase II trial of pre-operative Chemoradiotherapy with or without Cetuximab (ERBITUX) in locally-advanced Adenocarcinoma of the Rectum (RMCC)
12. **Phase II Study of Treatment Selection Based Upon Tumor Thymidylate Synthase Expression in Previously Untreated Patients with Metastatic Colorectal Cancer (CCRP)**
13. Phase II Study of AG-013736 in Combinations with Chemotherapy and Bevacizumab in Patients with Metastatic Colorectal Cancer Preceded by a Phase I Portion (FolFoxAG vs. FolFoxBev vs. FolFoxAGBev MCRC) (1st Line Metastatic) (RMCC)
14. **Phase II Study of Treatment Selection Based Upon Tumor Thymidylate Synthase Expression in Previously Untreated Patients with Metastatic Colorectal Cancer (RMCC)**
15. Ultrastaging of Early Cancer of the Large Bowel Using Intraoperative Lymphatic Mapping, Sentinel Node Analysis and Blood Testing (UCCC)
16. **Colorectal Cancer Family Registry (UCCC)**
17. LAPTOP-OC: A Phase II Trial of Lapatinib in Combination with Weekly Topotecan in Patients with Platinum-Refractory/Resistant Ovarian and Primary Peritoneal Carcinoma (CCRP)

HOTLINE: 1-888-729-0244

Colorado Cancer Research Program (CCRP) 303-777-2663; Denver Health (DH) 303-436-5774; Rocky Mountain Cancer Centers (RMCC) 1-888-259-7622; University of Colorado Cancer Center (UCCC) 720-848-0018

CancerPACT is a program presented by the Colorado Cancer Research Program, Colorado Cancer Coalition, Colorado Department of Public Health and Environment, Denver Health, Lorenzen Cancer Foundation, and University of Colorado Cancer Center

www.CancerPACT.org

B. Esophageal Cancer

1. **Oxaliplatin Plus Protracted Infusion 5-Fluorouracil and Radiation for Potentially Curable Esophageal Cancer: A Phase II Trial with Molecular Correlates (UCCC)**
2. Pilot Feasibility Trial of Preoperative Capecitabine, Oxaliplatin, Cetuximab and Radiation Therapy for Locally Advanced Esophageal Adenocarcinoma (UCCC)
3. **Phase II study of Temozolomide (SCH 52365) in subjects with advanced Aerodigestive tract cancers selected for Methylation of O6-Methyl-Guanine-DNA Methyltransferase (MGMT) promoter (UCCC)**
4. Phase II trial of Docetaxel plus Oxaliplatin (DOCOX) with or without Cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma (RMCC)

C. Gall bladder/ Bile duct Cancer

1. **Phase I Study of Bortezomib Given Intravenously Once Weekly Prior to And During Concurrent Fixed Dose Paclitaxel and Radiation in Patients with Locally Advanced, Non-Metastatic Pancreatic or Biliary Cancer (UCCC)**

D. Liver Cancer

1. **Phase I/II Dose Escalation Study of Extracranial Stereotactic Hypofractionated Radioablation for Liver Metastases (UCCC)**

E. Pancreatic Cancer

1. Phase II Adjuvant Trial of Efficacy, Immunogenicity, and Safety of GI-4000, an Inactivated Recombinant Saccharomyces Cerevisiae Expressing Mutant Ras Protein Combined with a Gemcitabine Regimen versus a Gemcitabine Regimen with Placebo, in Patients with post-resection R0/R1 Pancreatic Cancer with Tumor Sequence Confirmation of Ras Mutations (RMCC)
2. A Randomized, Phase II/III Study of TNFerade Biologics with 5-FU and Radiation Therapy for First Line Treatment of Unresectable Locally Advanced Pancreatic Cancer (UCCC)
3. **Randomized Phase I/II study with Gemcitabine and RTA 402 or Gemcitabine and Placebo for Patients with Unresectable Pancreatic Cancer (RMCC)**
4. Phase II Randomized, Double-Blind, Multicenter Trial of Amplimexon® plus Gemcitabine versus Gemcitabine plus Placebo in Patients With Metastatic Chemotherapy Naïve Pancreatic Adenocarcinoma (Stage IV) (RMCC)
5. **Safety and Efficacy of the Therapeutic Vaccine GI-4000 in Combination With Gemcitabine Versus Placebo for the Treatment of Non-Metastatic, Post-Resection Pancreas Cancer (RMCC)**
6. Phase I Trial of Gemcitabine/Capecitabine/ZD6474 in Advanced Solid Tumors With Expanded Cohort of Patients with Biliary or Pancreatic Malignancies (UCCC)
7. **Phase I Study of Bortezomib Given Intravenously Once Weekly Prior to And During Concurrent Fixed Dose Paclitaxel and Radiation in Patients with Locally Advanced, Non-Metastatic Pancreatic or Biliary Cancer (UCCC)**

HOTLINE: 1-888-729-0244

Colorado Cancer Research Program (CCRP) 303-777-2663; Denver Health (DH) 303-436-5774; Rocky Mountain Cancer Centers (RMCC) 1-888-259-7622; University of Colorado Cancer Center (UCCC) 720-848-0018

CancerPACT is a program presented by the Colorado Cancer Research Program, Colorado Cancer Coalition, Colorado Department of Public Health and Environment, Denver Health, Lorenzen Cancer Foundation, and University of Colorado Cancer Center

www.CancerPACT.org

4. Gynecologic Cancers

A. Cervical Cancer

1. Phase III, Randomized Trial of Weekly Cisplatin and Radiation Versus Cisplatin and Tirapazamine and Radiation in Stage IB2, IIA, IIB, IIIB and IVA Cervical Carcinoma Limited to the Pelvis (UCCC)
2. **Phase II Study of Intensity Modulated Radiation Therapy (IMRT) to the Pelvis +/- Chemotherapy for Post-operative Patients with either Endometrial or Cervical Carcinoma (UCCC)**
3. Phase II Study of Bevacizumab in Combination with Definitive Radiotherapy and Cisplatin Chemotherapy in Untreated Patients with Locally Advanced Cervical Carcinoma (DH, UCCC)
4. **Prospective Evaluation of Pelvic Exenteration in Patients with Recurrent Cervical Cancer (UCCC)**

B. Ovarian/Peritoneal Cancer

1. Phase III Randomized Trial of Maintenance Chemotherapy Comparing 12 Monthly Cycles of Single Agent Paclitaxel or Xyotax (CT-2103) (IND#70177) Versus No Treatment Until Documented Relapse in Women with Advanced Ovarian Or Primary Peritoneal Cancer (CCRP, RMCC, UCCC)
2. **Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (RHUMAB VEGF, NSC # 704865), IND # 7921) Followed by Placebo, Versus Carboplatin and Paclitaxel Plus (CCRP; UCCC)**
3. Randomized, Double Blind, Placebo Controlled, Multicenter Trial of Abagovomab Maintenance Therapy in Patients with Epithelial Ovarian Cancer after Complete Response to First Line Chemotherapy (UCCC)
4. **Phase III Trial of Carboplatin and Paclitaxel Plus Placebo vs Carboplatin and Paclitaxel Plus Concurrent Bevacizumab Followed By Placebo, Vs Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, In Women With Newly Diagnosed, Previously Untreated, Stage III or IV Epithelial Ovarian or Primary Peritoneal Cancer. (CCRP, RMCC)**
5. Phase II Randomized Study of the Effect of Zoledronic Acid versus Observation on Bone Mineral Density of the Lumbar Spine in Women who Elect to Undergo Risk-Reducing Surgery that Results in Removal of Both Ovaries (CCRP, RMCC)

C. Uterine Cancer

1. Whole Abdominal Radiotherapy versus Combination Doxorubicin-Cisplatin Chemotherapy in Advanced Endometrial Cancer. (UCCC)
2. **Molecular Staging Study of Endometrial Carcinoma (UCCC)**

HOTLINE: 1-888-729-0244

Colorado Cancer Research Program (CCRP) 303-777-2663; Denver Health (DH) 303-436-5774; Rocky Mountain Cancer Centers (RMCC) 1-888-259-7622; University of Colorado Cancer Center (UCCC) 720-848-0018

CancerPACT is a program presented by the Colorado Cancer Research Program, Colorado Cancer Coalition, Colorado Department of Public Health and Environment, Denver Health, Lorenzen Cancer Foundation, and University of Colorado Cancer Center

www.CancerPACT.org

5. Head & Neck Cancer

1. **Phase III, Multi-Center, Open-Label, Randomized Study to Compare the Overall Survival and Safety of Bi-Weekly Intratumoral Administration of INGN 201 Versus Weekly Methotrexate in 240 Patients with Refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN) [T301] (UCCC)**
2. Phase III Trial Comparing Sequential Therapy With TPF/Chemoradiation (ST) to Cisplatin-Based Chemoradiotherapy with Accelerated Concomitant Boost (CCRP, RMCC)
3. **Phase III, Randomized, Placebo-Controlled Trial of Docetaxel Vs Docetaxel Plus ZD1839 (Iressa) In Performance Status 2 or Previously Treated Patients With Recurrent or Metastatic Head and Neck Cancer (CCRP, RMCC)**
4. Phase III Trial of Concurrent Accelerated Radiation and Cisplatin Versus Concurrent Accelerated Radiation, Cisplatin, and Cetuximab (C225) [Followed by Surgery for Selected Patients] for Stage III and IV Head and Neck Carcinomas (CCRP, UCCC)
5. **Phase III Trial Comparing Sequential Therapy With TPF/Chemoradiation (ST) To Cisplatin-Based Chemoradiotherapy with Accelerated Concomitant Boost Radiotherapy (CRT) for Locally Advanced Squamous Cell Cancer of the Head and Neck (CCRP)**
6. Phase III, Randomized, Placebo-Controlled Trial of Docetaxel Vs Docetaxel Plus ZD1839 (Iressa) In Performance Status 2 or Previously Treated Patients With Recurrent or Metastatic Head and Neck Cancer (CCRP, UCCC)
7. **Phase II Study of Bortezomib in Metastatic Papillary Thyroid Carcinoma or Follicular Thyroid Carcinoma (UCCC)**
8. Phase II Study of Decitabine in Patients with Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Radioiodine (UCCC)
9. **Phase II Pivotal Trial of Anti-angiogenesis Agent AG013736 in Patients with I-Refractory Metastatic or Unresectable Locally Advanced Papillary Follicular or Hurthle cell Thyroid Cancer who are also Refractory to or Intolerant of or Have Clinical Contraindication to Doxorubicin Treatment (UCCC)**
10. An Investigator-Initiated, Multicenter, Randomized, Double-Blind Placebo-Controlled Design Study to Assess the Effectiveness of CeviMeline to Improve Oral Health in Patients with Xerostomia Secondary to Radiation Therapy for Treatment of Head and Neck Squamous Cell Carcinoma (UCCC)
11. **A Phase I Dose Escalation of Erlotinib Concurrently With Radiation Therapy in the Re-irradiation Setting for Head and Neck Cancer (DH)**

6. Lung Cancer

1. **Phase III, Multicenter, Placebo-Controlled, Double-Blind, Randomized Clinical Trial to Evaluate the Efficacy of Bevacizumab In Combination with Tarceva (Erlotinib) compared with Tarceva Alone for Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) After Failure of Standard First Line Chemotherapy (RMCC)**
2. Phase III Study of Single-agent Tarceva (Erlotinib) Following Complete Tumor Resection with or without Adjuvant Chemotherapy in Patients with Stage IB-IIIa Non-small Cell Lung Carcinoma who have EGFR-Positive Tumors (RMCC)
3. **Phase III Study of Docetaxel or Pemetrexed with or without Cetuximab in Patients with Recurrent or Progressive Non-Small Cell Lung Cancer after Platinum-Based Therapy (RMCC)**
4. Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (> 4 cm) – IIIa Non-Small Cell Lung Cancer (NSCLC) (CCRP, RMCC)

HOTLINE: 1-888-729-0244

Colorado Cancer Research Program (CCRP) 303-777-2663; Denver Health (DH) 303-436-5774; Rocky Mountain Cancer Centers (RMCC) 1-888-259-7622; University of Colorado Cancer Center (UCCC) 720-848-0018

CancerPACT is a program presented by the Colorado Cancer Research Program, Colorado Cancer Coalition, Colorado Department of Public Health and Environment, Denver Health, Lorenzen Cancer Foundation, and University of Colorado Cancer Center

www.CancerPACT.org

5. **Phase III Chemoprevention Trial of Selenium Supplementation in Persons with Resected Stage I Non Small Cell Lung Cancer (CCRP, RMCC)**
6. Phase III Comparison of Standard-Dose (60 Gy) Versus High-Dose (74 Gy) Conformal Radiotherapy with Concurrent and Consolidation Carboplatin/Paclitaxel in Patients With Stage IIIA/IIIB Non-Small Cell Lung Cancer. (CCRP)
7. **Phase II Trial of Erlotinib (Tarceva) in Combination with Stereotactic Body Radiation Therapy (SBRT) for Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) (UCCC)**
8. Phase II Study of Novel Oral Anti-Angiogenic Agent AZD2171 (NSC-732208) in Malignant Pleural Mesothelioma (UCCC)
9. **Phase II Randomized, Placebo-controlled, Double-blind, Multicenter Study with a Lead in Phase of Erlotinib With or Without SNDX-275 in Patients with Non-small Cell Lung Carcinoma After Failure In Up to Two Prior Chemotherapeutic Regimens for Advanced Disease (SNDX-275-0401) (Midtown and Lakewood only) (RMCC)**
10. Phase II Study of C225 (Cetuximab) for the Treatment of Patients with Advanced Bronchioalveolar Carcinoma (BAC) or Adenocarcinoma with BAC Features (CCRP; RMCC)
11. **Phase II, Randomized, Open-Label Trial of Biweekly Pemetrexed plus Gemcitabine vs. Pemetrexed or Pemetrexed plus Carboplatin in Relapsed Non Small Cell Lung Cancer (NSCLC) after Neoadjuvant or Adjuvant Chemotherapy (RMCC)**
12. Transitional Research Study Testing the Biology of Monocyte-Derived Dendritic Cells and Immune Effector Cells from Subjects with Advanced Renal Cell Cancer Treated with Sutent (Sunitinib) or Nexavar (Sorafenib) (UCCC)
13. **Phase II Trials of Pemetrexed in Patients With Selected Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) (DH)**
14. A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Addition of Bevacizumab (NSC-704865) in Three Cohorts of Patients With Inoperable Locally Advanced Stage III Non-Small Cell Lung Cancer (DH)
15. **Positron Emission Tomography Pre- and Post-treatment Assessment for Locally Advanced Non-small Cell Lung Carcinoma (UCCC)**
16. Phase II Randomized Chemoprevention Study of Iloprost vs Placebo in Patients at High Risk for Lung Cancer (UCCC)
17. Phase I/II Study of Pemetrexed Plus Bortezomib in Elderly Patients Age ≥ 70 Years with ECOG Performance Status 0-2 with Untreated Stages IIIB Malignant Effusion or Stage IV Non-Small Cell Lung Cancer (RMCC)
18. **Phase I, Open-Label, Dose Escalation Study of Weekly Dosing with BB-10901, followed by a Phase II Efficacy Expansion (small cell lung cancer, CD56+ small cell carcinoma of unknown origin or CD56+ non-pulmonary small cell carcinoma) (RMCC)**
19. Observational Study of Avastin in Combination with Chemotherapy for Treatment of Metastatic or Locally Advanced and Unresectable Colorectal Cancer and Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Excluding Predominant Squamous Cell Histology) (RMCC)
20. **Response of Intermediate Endpoint Biomarkers and Dysplastic Airway Epithelium to Chemotherapy or Targeted Therapy in Patients wit Lung Cancer (UCCC)**
21. Saliva mRNA Expression Profiling for Early Stage Non-Small Cell Lung Cancer Screening (UCCC)
22. **Biomarkers and Dysplastic Respiratory Epithelium (version B) (UCCC)**
23. Analysis of Intermediate Endpoint Biomarkers in the Respiratory Epithelium of Smokers Compared to Non-Smoking Controls (UCCC)
24. **Exploratory Analysis of Exhaled Nitric Oxide Concentration in Patients with Lung Cancer Receiving Thoracic Radiotherapy (UCCC)**
25. Lung Cancer Tissue Bank Protocol (UCCC)

HOTLINE: 1-888-729-0244

Colorado Cancer Research Program (CCRP) 303-777-2663; Denver Health (DH) 303-436-5774;
Rocky Mountain Cancer Centers (RMCC) 1-888-259-7622; University of Colorado Cancer
Center (UCCC) 720-848-0018

CancerPACT is a program presented by the Colorado Cancer Research Program, Colorado Cancer Coalition,
Colorado Department of Public Health and Environment, Denver Health, Lorenzen Cancer Foundation, and
University of Colorado Cancer Center

www.CancerPACT.org

26. Genetic Epidemiology of Lung Cancer: Gene Identification in High Risk Families (UCCC)
27. **A Phase II Randomized Study of Pemetrexed With Sorafenib Versus Pemetrexed Alone as Second-line Therapy in Patients With Advanced Non-Small Cell Lung Cancer (CCRP)**

7. Melanoma

1. Phase III Randomized, Double-Blind Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A 0201 Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma (RMCC).
2. **Phase III Randomized Study of Four Weeks High Dose IFN- α 2b in Stage T2b No, T3a-b, T4a-b No, and T1-4, N1a, 2a, 3 (microscopic) Melanoma (CCRP; UCCC)**
3. Phase III, Open Label, Randomized, Comparative Study of Tumor Necrosis Factor- α Inhibitor and Either Dacarbazine or Temozolomide in Patients with Advanced Melanoma (UCCC)
4. **Phase III Multi-Institutional Randomized Study of Immunization with the gp100: 209-217(210M) Peptide Followed by High Dose IL-2 vs. High Dose IL-2 Alone in Patients with Metastatic Melanoma (UCCC)**
5. Four Weeks of High Dose IFN Alpha 2B in Stage T3-T4 or N1 (Microscopic) Melanoma (RMCC)
6. **Phase II Trial of BAY 43-9006 (Sorafenib; NSC-724772) in Combination with Carboplatin and Paclitaxel in Patients with Metastatic Uveal Melanoma (UCCC)**
7. Phase II Study of the Efficacy, Safety and Immunogenicity of Oncovex (GM-CSF) In Patients With Inoperable Malignant Melanoma (UCCC)
8. **Malignant Melanoma Tissue Bank (UCCC)**
9. Sleep Management Program to Reduce Sleep Disturbances during Melanoma Treatment: A Pilot Feasibility Study (UCCC)

8. Prostate Cancer

1. **Phase III protocol of Androgen Suppression (AS) and 3DCRT/IMRT versus AS & 3DCRT/IMRT followed by chemo w/Docetaxel and Prednisone for localized high risk Prostate Cancer (CCRP, UCCC)**
2. Phase III Study of Intermittent Androgen Deprivation in Patients with Stage D2 Prostate Cancer (CCRP, RMCC, UCCC)
3. **Phase III study of Docetaxel and Atrasentan vs Docetaxel and Placebo for patients with advanced hormone refractory prostate cancer (UCCC)**
4. Phase III Study of Early Versus Standard Zoledronic Acid to Prevent Skeletal Related Events in Men with Prostate Cancer Metastatic to Bone (UCCC)
5. **Phase III Study of Hypofractionated 3-D-CRT/IMRT vs Conventionally Fractionated 3D-CRT/IMRT in Patients With Favorable Risk Prostate Cancer (CCRP, UCCC)**
6. Phase III Trial of Docetaxel in Combination with CG1940 and CG8711 versus Docetaxel and Prednisone in Taxane-naïve patients with Metastatic Hormone Refractory Prostate Cancer with Pain (UCCC)
7. **Phase III Randomized Open Label Multi Center Study of XRP6258 at 25 mg/m² in Combination with Prednisone every 3 weeks Compared to Mitoxantrone in Combination with Prednisone for the Treatment of Hormone Refractory Metastatic Prostate Cancer Previously Treated with Taxotere Containing Regime (UCCC)**

HOTLINE: 1-888-729-0244

Colorado Cancer Research Program (CCRP) 303-777-2663; Denver Health (DH) 303-436-5774; Rocky Mountain Cancer Centers (RMCC) 1-888-259-7622; University of Colorado Cancer Center (UCCC) 720-848-0018

CancerPACT is a program presented by the Colorado Cancer Research Program, Colorado Cancer Coalition, Colorado Department of Public Health and Environment, Denver Health, Lorenzen Cancer Foundation, and University of Colorado Cancer Center

www.CancerPACT.org

8. Phase II study of mitoxantrone vs. mitoxantrone with cetuximab in metastatic androgen independent prostate cancer (AIPC) previously treated with docetaxel-based chemotherapy (RMCC)
9. **The Application of Target Cryotherapy in the Treatment of Organ Confined Prostate Cancer (UCCC)**
10. Phase II study of CNTO 328. Monoclonal antibody against Interleukin-6 (IL-6) in patients with hormone refractory prostate cancer (UCCC)
11. **Pilot Biomarker Study of Oral Silybin-Phytosome Followed by Prostatectomy in Patients with Localized Prostate Cancer (UCCC)**
12. Phase II Randomized, Double Blind, Placebo Controlled, Multicenter Study Comparing AT-101 in Combination with Docetaxel and Prednisone versus Docetaxel and Prednisone in Men with Chemotherapy Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC) (RMCC)
13. **Phase II Study of a Weekly Schedule of BMS-247550 for Patients with Hormone Refractory Prostate Cancer (CCRP, RMCC)**
14. Phase I Study of the Combination of Taxotere and Radiation in Prostate Cancer. (RMCC)
15. **Cell Kinetic Study of Bromodeoxyuridine (BrdU) in Prostate Cancer (UCCC)**
16. Modified Prostate Cancer Biopsy Method (UCCC)
17. **Study to Define Protein Signatures for Prostate Cancer (biopsy) (UCCC)**
18. Study to Define Protein Signatures for Prostate Cancer Progression (UCCC)
19. **Anabolic/Catabolic Balance in Skeletal Muscle of Men with Prostate Cancer (UCCC)**

9. Sarcoma

1. **Osteosarcoma biology protocol (UCCC)**
2. European Ewing Tumor Working Initiative of National Groups, Ewing Tumor Studies 1999 (EURO-E.W.I.N.G.99) (UCCC)

10. Urologic Cancers (other)

A. Bladder/Urethral Cancer

1. **Phase III Randomized Study of Intravesical Gemcitabine Hydrochloride Immediately After Transurethral Resection of the Bladder Tumor in Patients With Newly Diagnosed or Recurrent Superficial Transitional Cell Bladder Cancer (UCCC)**
2. Phase II Study of Intravesical Gemcitabine in Patients With Recurrent Superficial Transitional Cell Carcinoma of the Bladder That Has Failed Prior Intravesical Bacillus Calmette-Guerin (UCCC)
3. **Trial of Single-Dose Intravesical EOquin® as a Surgical Adjuvant Instilled in the Early Postoperative Period in Patients Undergoing Transurethral Resection for Noninvasive Bladder Cancer (CCRP)**
4. Phase II Trial of Lapatinib Versus Placebo in Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy Exists (CCRP)

HOTLINE: 1-888-729-0244

Colorado Cancer Research Program (CCRP) 303-777-2663; Denver Health (DH) 303-436-5774; Rocky Mountain Cancer Centers (RMCC) 1-888-259-7622; University of Colorado Cancer Center (UCCC) 720-848-0018

CancerPACT is a program presented by the Colorado Cancer Research Program, Colorado Cancer Coalition, Colorado Department of Public Health and Environment, Denver Health, Lorenzen Cancer Foundation, and University of Colorado Cancer Center

www.CancerPACT.org

B. Kidney Cancer

1. A Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib versus Sorafenib versus Placebo in Patients with Resected Renal Cell Carcinoma (DH)
2. **Phase II Study of Perifosine for Patients with Metastatic Carcinoma of the Kidney who have Progressed on a VEGF Receptor Inhibitor (RMCC)**
3. Transitional Research Study Testing the Biology of Monocyte-Derived Dendritic Cells and Immune Effector Cells from Subjects with Advanced Renal Cell Cancer Treated with Sutent (Sunitinib) or Nexavar (Sorafenib) (UCCC)
4. **Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma (CCRP, RMCC)**

II. Hematologic Cancers

1. Leukemia

1. Phase III Randomized, Double-Blind, Controlled Study Comparing Clofarabine and Cytarabine Versus Cytarabine Alone in Adult Patients 55 Years and Older with Acute Myelogenous Leukemia (AML) Who Have Relapsed or are Refractory after Receiving up to Two Prior Induction Regimens (UCCC)
2. **Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Inductions Failure (CCRP, RMCC)**
3. Phase II Trial of Pentostatin, Cyclophosphamide and Rituximab (PCR) followed by Campath-1H for Previously Treat Relapsed or Refractory Patients with Chronic Lymphocytic Leukemia (CCRP; RMCC)
4. **Phase III Randomized open-label study of 400mg versus 800mg of Gleevec/Glivec (imatinib mesylate) in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase (CML-CP) using molecular endpoints (RMCC)**
5. Phase III Study of Imatinib versus Nilotinib in Adults with Newly Diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP) (RMCC)
6. **Phase II Study of Combination Bortezomib (VELCADE®PS-341) and Rituximab in Patients with Previously Untreated and Relapsed/Refractory Waldenstrom's Macroglobulinemia (RMCC)**
7. Phase II Study of Initial Treatment with Methotrexate in Large Granular Lymphocytic (LGL) Leukemia (CCRP; RMCC)
8. **Phase II Trial of Azacitadine With or Without the Histone Deacetylase Inhibitor MS-275 for the Treatment of Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (dysplastic type) and Acute Myeloid Leukemia with Multilineage Dysplasia (CCRP, RMCC)**
9. Phase II Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Alemtuzumab (CAMPATH, MabCampath) in Patients with Previously Treated B-Cell Chronic Lymphocytic Leukemia (RMCC, UCCC)
10. **Phase II study of safety and biological activity of GCS-100 in subjects with CLL (PR-CS008) (RMCC)**

HOTLINE: 1-888-729-0244

Colorado Cancer Research Program (CCRP) 303-777-2663; Denver Health (DH) 303-436-5774; Rocky Mountain Cancer Centers (RMCC) 1-888-259-7622; University of Colorado Cancer Center (UCCC) 720-848-0018

CancerPACT is a program presented by the Colorado Cancer Research Program, Colorado Cancer Coalition, Colorado Department of Public Health and Environment, Denver Health, Lorenzen Cancer Foundation, and University of Colorado Cancer Center

www.CancerPACT.org

11. Classification of Acute Lymphoblastic Leukemia (UCCC)
12. **High Risk B-Precursor Acute Lymphoblastic Leukemia (UCCC)**
13. Feasibility trial of unrelated umbilical cord transplantation in children and adults with leukemia and other hematologic, immunologic and metabolic disorders (UCCC)
14. **Phase I, Multi-Dose Study of SGN-33 (anti-huCD33 mAb; HuM195; lintuzumab) in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome (RMCC)**
15. A Phase III Trial in Adult Acute Myeloid Leukemia: Daunorubicin Dose-Intensification Prior to Risk-Allocated Autologous Stem Cell Transplantation (CCRP)

2. Lymphoma

1. **Observational Study of Treatment, Outcomes, and Prognosis in Patients With Follicular Non-Hodgkin's Lymphoma (RMCC)**
2. Phase III, Randomized, Double-Blind Study of Galiximab in Combination with Rituximab Compared with Rituximab in Combination with Placebo for the Treatment of Subjects with Relapsed or Refractory, Follicular Non Hodgkin's Lymphoma (CCRP, RMCC)
3. **Phase III Trial Comparing Two Different Rituximab Dosing Regimens for Patients with Low Tumor Burden Indolent Non-Hodgkin's Lymphoma (CCRP; RMCC)**
4. Phase III Trial Comparing Early High Dose Chemoradiotherapy and an Autologous Stem Cell Transplant to Conventional Dose CHOP Chemotherapy (With Poss. Late Auto.SCT) for patients with Diffuse Aggressive NHL in the High-Intermediate and High Risk Inter. Class Prognostic Groups (RMCC)
5. **Phase II Trials of R-CHOP Followed by Zevalin Radioimmunotherapy for Patients with Previously Untreated Stages I and II CD20+ Diffuse Large Cell Non-Hodgkin's Lymphoma (CCRP, RMCC)**
6. Phase II Study of Velcade (bortezomib) in Combination with Bendamustine and Rituximab in Subjects with Relapsed or Refractory Follicular Lymphoma (RMCC)
7. **Phase II Trial of Standard Dose Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) and Rituximab Plus Bevacizumab for Advanced Stage Diffuse Large B-Cell NHL (UCCC)**
8. Open Label, Dose Escalation Followed by Double-blind, Randomized, Two-Dose Parallel Group, Multi-center Clinical Trial of HuMax-CD4, a Fully Human Monoclonal Anti-CD4 Antibody, in Patients with Mycosis Fungoides type CTCL (Stage IB-IVB) Who Are Refractory (UCCC)
9. **Phase II Study of CCI-779 in Combination with Rituximab in Patients with Relapsed or Refractory Mantle Cell Lymphoma (CCRP; RMCC)**
10. Phase II Study of VcR-CVAD with Rituximab Maintenance for Untreated Mantle Cell Lymphoma. (CCRP, RMCC)
11. **Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability of Romidepsin (Depsipeptide, FK228) in Progressive or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (RMCC)**
12. A Phase II Study of PDX101 (NSC-726630) in Relapsed and Refractory Aggressive B-Cell Lymphoma (DH)
13. **Phase I/II Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Have Been Treated With a Prior Rituximab-Containing Regimen (GALANT) (RMCC)**
14. Phase I Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin (RMCC)

HOTLINE: 1-888-729-0244

Colorado Cancer Research Program (CCRP) 303-777-2663; Denver Health (DH) 303-436-5774; Rocky Mountain Cancer Centers (RMCC) 1-888-259-7622; University of Colorado Cancer Center (UCCC) 720-848-0018

CancerPACT is a program presented by the Colorado Cancer Research Program, Colorado Cancer Coalition, Colorado Department of Public Health and Environment, Denver Health, Lorenzen Cancer Foundation, and University of Colorado Cancer Center

www.CancerPACT.org

3. Myeloma

1. Phase III Randomized, Double-Blind Study of Maintenance Therapy With CC-5013 or Placebo Following Autologous Stem Cell Transplantation For Multiple Myeloma (**CCRP, RMCC**)
2. **Phase IIIb Study of Three Treatment Regimens in Patients with Previously Untreated Multiple Myeloma who are not Considered Candidates for High-Dose Chemotherapy and Autologous Stem Cell Transplantation: VELCADE, Thalidomide, and dexamethasone (VTD) versus VELCADE and dexamethasone (VD) versus VELCADE, Melphalan, and prednisone (VMP) (RMCC)**
3. Phase III Trial of Consolidation Therapy with Bortezomib (Velcade®) - Lenalidomide (Revlimid®) - Dexamethasone (VRD) versus Bortezomib (Velcade®) -Dexamethasone (VD) for Patients With Multiple Myeloma Who Have Completed a Dexamethasone Based Induction Regimen (CCRP, RMCC)
4. **Phase III Randomized, Open-Label Clinical Trial of Tanespimycin (KOS-953) plus Bortezomib Compared to Bortezomib Alone in Patients with Multiple Myeloma in First Relapse (TIME-1) (RMCC)**
5. Double Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of AMG 531 Treatment of Subjects with Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Receiving Lenalidomide (RMCC)
6. **Phase II Randomized, Blinded, Placebo-Controlled, Multicenter Study of Bevacizumab in Combination with Bortezomib in Patients with Relapsed or Refractory Multiple Myeloma (RMCC)**
7. Phase 1/2 Study of VELCADE(Bortezomib), Dexamethasone, and Revlimid (Lenalidomide)(VDR) versus VELCADE, Dexamethasone, Cyclophosphamide, and Revlimid (VDCR) versus VELCADE, Dexamethasone, and Cyclophosphamide (VDC) in Subjects with Previously Untreated Multiple Myeloma (RMCC)
8. **Phase II Open-label Trial of Velcade in Velcade-naive Patients with Multiple Myeloma who have undergone High-dose Melphalan Therapy followed by Autologous Peripheral Blood Stem Cell Transplantation and Failed to Achieve a Complete Response (RMCC)**
9. Phase I Combination Trial of SGN-33 (anti-huCD33 mAb; HuM195; lintuzumab) and Lenalidomide (Revlimid) in Patients with Myelodysplastic Syndromes (RMCC)
10. **Phase I Study of SGN-40 (anti-huCD40 mAb), Lenalidomide (Revlimid, cc-5013), and Dexamethasone in Patients with Multiple Myeloma (CCRP, RMCC)**

III. Other

1. Phase III Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin alfa for Cancer Patients with Chemotherapy-Associated Anemia (**CCRP**)
2. **Phase III Randomized, Placebo-controlled, Double-blind Trial to Determine the Effectiveness of a Urea/Lactic Acid-Based Topical Keratolytic Agent and Vitamin B-6 for Prevention of Capecitabine-Induced Hand and Foot Syndrome (CCRP)**
3. Phase III Randomized, Double-Blind, Placebo-Controlled Study of Pilocarpine for Vaginal Dryness (CCRP, RMCC)

HOTLINE: 1-888-729-0244

Colorado Cancer Research Program (**CCRP**) **303-777-2663**; Denver Health (**DH**) **303-436-5774**;
Rocky Mountain Cancer Centers (**RMCC**) **1-888-259-7622**; University of Colorado Cancer
Center (**UCCC**) **720-848-0018**

CancerPACT is a program presented by the Colorado Cancer Research Program, Colorado Cancer Coalition,
Colorado Department of Public Health and Environment, Denver Health, Lorenzen Cancer Foundation, and
University of Colorado Cancer Center

www.CancerPACT.org

4. **Part II: A Randomized Controlled Trial of Research Study Navigators versus Usual Care for the Enrollment of Older Adults in Early Phase Trials (UCCC)**
5. Phase I Study of Bortezomib and Concurrent External Beam Radiation in Patients with Advanced Solid Malignancies (UCCC)
6. **Phase I Safety Pharmacokinetic and Pharmacodynamic study of PF-02341066 a C-Met/HGFR selective Tyrosine Kinase inhibitor administered orally to patients with advanced cancer (UCCC)**
7. Phase I dose escalation study of daily oral OSI-930 in patients with advanced solid tumors (UCCC)
8. **Phase I Study of SU011248 In Combination With Pemetrexed, Pemetrexed/Cisplatin and Pemetrexed/Carboplatin in Patients With Advanced Solid Malignancies (UCCC)**
9. Phase I Study of SU011248 in Combination with Oxaliplatin, Leucovorin, and 5-Fluorouracil in Patients With Advanced Solid Malignancies (UCCC)
10. **Phase 1, Open-Label, Dose-Escalation Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of 2 Dosing Schedules of PF-00299804 in Patients with Advanced Malignant Solid Tumors (UCCC)**
11. Phase I Study of PDX101 in Combination with Bortezomib (PS-341) in patients with Advanced Solid Tumors and Lymphoma (UCCC)
12. **Phase I open label multi centre study to assess the safety tolerability and pharmacokinetics of a solid oral dosage formulation (capsule) of AZD6244 in patents with advanced solid malignancies (UCCC)**
13. Phase 1A open label dose escalation study of the safety and Pharmacokinetics of GDC-0152 an IAP protein antagonist administered intravenously to patients with locally advanced or metastatic malignancies (UCCC)
14. **Phase IB dose Escalation of Study of the Safety and Pharmacokinetics of Apomab in Combination with Cetuximab and Irinotecan Chemotherapy in Patients with Previously Treated Colorectal Cancer (UCCC)**
15. Phase I Open Label Study of Rhumab IGFR in Patients with Advanced Solid Tumors for which Standard Therapy either Does Not Exist or Has Been Proven Ineffective or Intolerable (UCCC)
16. **Phase I Multiple Ascending Dose (MAD) of R4733 Administered Orally in Patients with Refractory Metastatic or Locally Advanced Solid Tumors (UCCC)**
17. Phase I Trial to Determine the Safety and Pharmacokinetics/ Pharmacodynamics of RDEA119 a MEK Inhibitor in Advanced Cancer Patients (UCCC)
18. **Phase I Study of AZD4877 in Patients with Advanced Cancer (UCCC)**
19. Phase I Study of CDK Inhibitor R547 for Solid Tumors (UCCC)
20. **Phase I , Open-Label, Dose Escalation Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of PF-00562271 in Patients with Advanced Non-Hematologic Malignancies (UCCC)**
21. Phase I TST10088 for Advanced Incurable Solid Tumors (UCCC)
22. **Single-Center Open-Label, Dose-Escalation Safety and Pharmacokinetic Study of ENMD-1198 Administered Orally to Patients with Advanced Cancer (UCCC)**
23. Phase I KOS-1022 for Advanced Solid Tumors (UCCC)
24. **Phase 1, Open-Label, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of NKTR-102 (NKT-10002) in Patients with Refractory Solid Tumors (RMCC)**
25. Prospective Investigation of Definitive Targeted Therapy for Solid Malignancies with Oligometastases (RMCC)
26. **Exploratory, Randomized, Placebo-Controlled Trial of Depot Octreotide (Sandostatin LAR ® Depot) for Symptomatic Ascites in Cancer Patients (CCRP, RMCC)**
27. Gist Registry- observational database for all Gist tumors (RMCC)

HOTLINE: 1-888-729-0244

Colorado Cancer Research Program (CCRP) 303-777-2663; Denver Health (DH) 303-436-5774;
Rocky Mountain Cancer Centers (RMCC) 1-888-259-7622; University of Colorado Cancer
Center (UCCC) 720-848-0018

CancerPACT is a program presented by the Colorado Cancer Research Program, Colorado Cancer Coalition,
Colorado Department of Public Health and Environment, Denver Health, Lorenzen Cancer Foundation, and
University of Colorado Cancer Center

www.CancerPACT.org